Tools for Practice Outils pour la pratique


#145 Exercise and Cardiovascular Disease: Getting to the heart of the matter


CLINICAL QUESTION
QUESTION CLINIQUE
How effective is exercise in reducing cardiovascular disease?


BOTTOM LINE
RÉSULTAT FINAL
In patients with cardiovascular disease (CVD), exercise may reduce the risk of dying from CVD for one in 32 people at 48 months and heart failure admissions for one in 14 heart failure patients at 27 months. It is cost effective and improves quality of life.   



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Randomized controlled trial (RCT) of 101 men with stable angina, randomized to single vessel percutaneous coronary intervention (PCI) or exercise bike (targeting 70% symptom-limited maximum heart rate for 20 minutes daily plus 60 minutes group session weekly).1 At 12 months: 
    • CVD events (CVD death, stroke, myocardial infarction, bypass, additional PCI, new angina hospitalization) significantly lower in bicycle group: 30% PCI versus 12% bicycleNumber Needed to Treat (NNT)=6.   
    • Cost: Exercise $3,708 versus PCI $6,086. 
  • Systematic review of RCTs of exercise-based cardiac rehabilitation:2 
    • Systematic review (47 RCTs10,794 patients) in coronary heart disease found significant relative reductions in trials >12 months:  
      • 13% for total mortality (NNT=59 at 33 months).2,3 
      • 26% for CVD mortality (NNT=32 at 48 months).2,3 
      • Other outcomes not statistically significantly different.2,3 
      • 7/10 RCTs examining quality of life found improvement with exercise.3 
    • Systematic review (33 RCTs, 4,740 patients) in heart failure found relative reductions in: 
      • 39% for heart failure admissions (NNT=14 at 27 months).2,4 
      • 11/19 RCTs examining quality of life found improvement with exercise.4  
      • Exercise was cost effective.4 
  • Another systematic review found similar benefits.5 
    • Also reduced risk of reinfarction: Odds Ratio 0.53 (95% Confidence Interval 0.38-0.76).5 
  • Systematic review in primary prevention: No RCTs identified.6   
  CONTEXT: 
  • Not possible to blind trials, and blinding of outcome assessors is rare.3,4 Losses to follow-up are high (example: 21-48%).3 
  • Indirect comparisons suggest CVD benefits of exercise are similar to individual drugs.7 
  • For mortality, fitness level appears more important than body weight.8 
  • Cohort data suggests unfit individuals who become fit see reductions in mortality.9,10  
  • Guidelines recommend and cohort data support at least 150 minutes of moderate to high intensity exercise per week, or 30-60 minutes most days of the week (includes brisk walking).11,12


Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Adrienne J Lindblad BSP ACPR PharmD
  • Doug Klein MD CCFP MSc
  • Shweta Dhawan MPH HBSc

1. Hambrecht R, Walther C, Möbius-Winkler S, et al. Circulation. 2004; 109:1371-8.

2. Anderson L, Taylor RS. Cochrane Database Syst Rev. 2014; 12:CD011273.

3. Heran BS, Chen JMH, Ebrahim S, et al. Cochrane Database Syst Rev. 2011; 7:CD001800.

4. Taylor RS, Sagar VA, Davies ET, et al. Cochrane Database Syst Rev. 2014; 4:CD003331.

5. Lawler PR, Filion KB, Eisenberg MJ. Am Heart J. 2011; 162:571-84.

6. Seron P, Lanas F, Pardo Hernandez H, et al. Cochrane Database Syst Rev. 2014; 8:CD009387.

7. Naci H, Ioannidis JPA. BMJ. 2013; 347:f5577.

8. Barry VW, Baruth M, Beets MW, et al. Prog Cardiovasc Dis. 2014; 56(4):382-90.

9. Erikssen G, Liestøl K, Bjørnholt J, et al. Lancet. 1998 Sep 5; 352(9130):759-62.

10. Blair SN, Kohl HW 3rd, Barlow CE, et al. JAMA. 1995 Apr 12; 273(14):1093-8.

11. Towards Optimized Practice. Prevention and management of cardiovascular disease risk in primary care. Available at: http://www.topalbertadoctors.org/download/1655/Lipid%20Pathway%20CPG.pdf?_20150624162113. Accessed June 24, 2015.

12. Sattelmair J, Pertman J, Ding EL, et al. Circulation. 2011; 124(7):789-95.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.